Evaluation of oral administration of Peganum in nocturia in patients with benign prostatic hyperplasia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014091419151N1

Enrollment

Registered

2014-09-19

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperplasia of prostate. Hyperplasia of prostate

Interventions

Intervention 1: Intervention group will be used of harmala seeds1 gr orally twice daily. Intervention 2: the control group did not receive any treatment.

Treatment - Drugs

Intervention group will be used of harmala seeds1 gr orally twice daily.

the control group did not receive any treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with benign prostatic enlargement. Exclusion criteria: patients undergoing surgery; a significant anomaly functional or anatomical urinary tract; thyroid dysfunction; prostate cancer; patients with mental disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease of nocturia. Timepoint: 1 months latter. Method of measurement: examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirani Majid

Shahrekord University of Medical Sciences

keivaniz@yahoo.com+98 38 1333 0065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026